Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Add as a preferred source on Google
MIAMI, May 01, 2018 -- OPKO Health, Inc. (NASDAQ:OPK) today announced the appointment of Geoff Monk as General Manager with overall responsibility for BioReference Laboratories (BRL), an OPKO Health company and the third largest clinical laboratory in the United States. Mr. Monk brings to BRL more than 20 years of operational, business strategy and technical experience. Previously, Mr. Monk worked as Managing Director of the New York and New Jersey unit of Quest Diagnostics, with P&L responsibility for Quest’s largest and most profitable business unit.
“Geoff has built an enviable track record of operational excellence and has delivered consistently impressive results. We are delighted to have Geoff join our team,” stated Phillip Frost, Chairman and Chief Executive Officer of OPKO Health.
Mr. Monk holds an MA in engineering from Cambridge University.
About OPKO Health, Inc.
OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400-person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA-approved treatment for secondary hyperparathyroidism in stage 3 and 4 chronic kidney disease patients with vitamin D insufficiency (launched in November 2016), OPK88003, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity which is a clinically advanced drug candidate among the new class of GLP-1 glucagon receptor dual agonists, OPK88004, a SARM (Selective Androgen Receptor Modulator) for treating BPH (Benign Prostatic Hypertrophy), OPK88002, a NK-1 antagonist to treat pruritus (itching) in dialysis patients, and OPK88001, a proprietary oligonucleotide to treat Dravet Syndrome. In addition, the Company is advancing its CTP technology, which includes a long acting hGH-CTP, a once weekly human growth hormone injection (in phase 3 and partnered with Pfizer). OPKO also has production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.
CONTACTS:
Company
OPKO Health, Inc.
David Malina, 305-575-4100
Investor Relations
Investors
LHA Investor Relations
Miriam Weber Miller, 212-838-3777
[email protected]
or
Bruce Voss, 310-691-7100
[email protected]
